Peptron FY 2025 Annual ReportBeta
Peptron annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Peptron FY 2025 Annual Report Analysis
Business Overview
- • Business model: peptide engineering and long-acting smart drug platform with GMP mass production for clinical and commercial supply
- • New product sales: KRW 910.6M revenue from newly launched long-acting drug (prostate cancer generic) domestic sales in FY2025
Management Discussion & Analysis
- • Revenue KRW 5.6B (+78.76% YoY), operating loss KRW 27.26B (margin -377.25%), net loss KRW 13.8B (-37% YoY)
- • Bio segment revenue KRW 3.9B (+76.87%), operating loss increased by KRW 4.025B (24.30%) due to increased personnel-driven R&D expenses
Risk Factors
- • USD 10% exchange rate move → ±KRW 191.6M pre-tax profit impact, up from ±KRW 29.9M in prior year
- • KRW 35.9B financial liabilities maturing across all buckets, up from KRW 10.7B prior year, driven by KRW 24.2B convertible bonds
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding